Predicting survival of children with CNS tumors using proton magnetic resonance spectroscopic imaging biomarkers

International Journal of Oncology

Volumn 30, Issue 3, 2007, Pages 651-657

  Marcus, Karen J ^a   Astrakas, Loukas G ^a   Zurakowski, David ^a   Zarifi, Maria K ^a   Mintzopoulos, Dionyssios ^a   Poussaint, Tina Young ^a   Anthony, Douglas C ^a   De Girolami, Umberto ^a   Black, Peter McL ^a   Tarbell, Nancy J ^b   Tzika, A Aria ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Pathology and Anatomical Sciences Missouri Columbia ^*  (United States)

Author keywords

Brain central nervous system cancers; Diagnostic imaging; Magnetic resonance spectroscopic imaging; NMR; Pediatric cancers; Survival; Tumor biomarkers

Indexed keywords

PROTON; TUMOR MARKER;

ADOLESCENT; ALGORITHM; ARTICLE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; FEMALE; HUMAN; INFANT; MALE; METABOLISM; METHODOLOGY; MORTALITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ALGORITHMS; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROPORTIONAL HAZARDS MODELS; PROTONS; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33947715298     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.3.651     Document Type: Article

References (56)

1. Khatua S and Jalali R: Recent advances in the treatment of childhood brain tumors. Pediatr Hematol Oncol 22: 361-371, 2005. (Pubitemid 40993599)
2. Bleyer W: What can be learned about childhood cancer from 'Cancer Statistics Review 1973-1988'. Cancer 71: 3229-3236, 1993.
3. Pollack I: Brain tumors in children. N Engl J Med 331: 1500-1507, 1994.
4. Kramer ED, Vezina LG, Packer RJ, Fitz CR, Zimmerman RA and Cohen MD: Staging and surveillance of children with central nervous system neoplasms: recommendations of the Neurology and Tumor Imaging Committees of the Children's Cancer Group. Pediatr Neurosurg 20: 253-262, 1994.
5. Jenkin D, Shabanah MA, Shail EA, et al: Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phys 47: 573-584, 2000.
6. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442, 2002.
7. Pollack IF, Finkelstein SD, Woods J, et al: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346: 420-427, 2002. (Pubitemid 34437697)
8. Arvanitis D, Malliri A, Antoniou D, Linardopoulos S, Field JK and Spandidos DA: Ras p21 expression in brain tumors: elevated expression in malignant astrocytomas and glioblastomas multiforme. In Vivo 5: 317-321, 1991.
9. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P and Pomeroy SL: Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 22: 994-998, 2004. (Pubitemid 41095030)
10. Nutt CL, Mani DR, Betensky RA, et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63: 1602-1607, 2003.
11. Harwood-Nash DC: Primary neoplasms of the central nervous system in children. Cancer 67: 1223-1228, 1991.
12. Tzika AA, Astrakas LG, Zarifi MK, et al: Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors. Cancer 100: 1246-1256, 2004. (Pubitemid 38325953)
13. Preul MC, Caramanos Z, Collins DL, et al: Accurate, non-invasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 2: 323-325, 1996. (Pubitemid 26080653)
14. Tzika AA, Vajapeyam S and Barnes PD: Multivoxel proton MR spectroscopy and hemodynamic MR imaging of childhood brain tumors: preliminary observations. AJNR Am J Neuroradiol 18: 203-218, 1997. (Pubitemid 27082196)
15. Lazareff JA, Bockhorst KH, Curran J, Olmstead C and Alger JR: Pediatric low-grade gliomas: prognosis with proton magnetic resonance spectroscopic imaging. Neurosurgery 43: 808-817, 1998. (Pubitemid 28436325)
16. Tzika AA, Zarifi MK, Goumnerova L, et al: Neuroimaging in pediatric brain tumors: Gd-DTPA-enhanced, hemodynamic, and diffusion MR imaging compared with MR spectroscopic imaging. AJNR Am J Neuroradiol 23: 322-333, 2002. (Pubitemid 34160445)
17. Nelson SJ: Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2: 497-507, 2003.
18. Tzika AA, Astrakas LG, Zarifi MK, et al: Multiparametric MR assessment of pediatric brain tumors. Neuroradiology 45: 1-10, 2003. (Pubitemid 36700808)
19. Astrakas LG, Zurakowski D, Tzika AA, et al: Non-invasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors. Clin Cancer Res 10: 8220-8228, 2004. (Pubitemid 40053381)
20. Nelson SJ: Magnetic resonance spectroscopic imaging. Evaluating responses to therapy for gliomas. IEEE Eng Med Biol Mag 23: 30-39, 2004.
21. Hourani R, Horska A, Albayram S, et al: Proton magnetic resonance spectroscopic imaging to differentiate between non-neoplastic lesions and brain tumors in children. J Magn Reson Imaging 23: 99-107, 2006.
22. Butowski NA, Sneed PK and Chang SM: Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 24: 1273-1280, 2006.
23. Cao Y, Sundgren PC, Tsien CI, Chenevert TT and Junck L: Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 24: 1228-1235, 2006.
24. Thomas MA, Ryner LN, Mehta MP, Turski PA and Sorenson JA: Localized 2D J-resolved 1H MR spectroscopy of human brain tumors in vivo. J Magn Reson Imaging 6: 453-459, 1996.
25. Binesh N, Yue K, Fairbanks L and Thomas MA: Reproducibility of localized 2D correlated MR spectroscopy. Magn Reson Med 48: 942-948, 2002.
26. Bottomley PA: Selective volume method for performing localized NMR spectroscopy. US patent 4 480 228, 1984.
27. Nelson SJ and Brown TR: A new method for automatic quantification of 1-D spectra with low signal to noise ratio. J Magn Reson 75: 229-243, 1987.
28. Weinstein MC and Fineberg HV: Clinical decision analysis. W.B. Saunders, Philadelphia, PA, 1980.
29. Medina LS, Aguirre E and Zurakowski D: Introduction to evidence-based imaging. Neuroimaging Clin North Am 13: 157-165, 2003.
30. Pepe MS and Thompson ML: Combining diagnostic test results to increase accuracy. Biostatistics 1: 123-140, 2000.
31. Obuchowski NA: Receiver operating characteristic curves and their use in radiology. Radiology 229: 3-8, 2003.
32. Hanley JA and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
33. Hanley JA and McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843, 1983.
34. Hosmer DW and Lemeshow S: Applied logistic regression. John Wiley & Sons, NY, 1989.
35. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958.
36. Cox DR: Regression models and life tables (with discussion). J Roy Stat Soc B 34: 187-220, 1972.
37. Louis DN, Holland EC and Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 159: 779-786, 2001.
38. Tzika AA, Cheng LL, Goumnerova L, et al: Biochemical characterization of pediatric brain tumors by using in vivo and ex vivo magnetic resonance spectroscopy. J Neurosurg 96: 1023-1031, 2002.
39. Fountas KN, Kapsalaki EZ, Vogel RL, Fezoulidis I, Robinson JS and Gotsis ED: Non-invasive histologic grading of solid astrocytomas using proton magnetic resonance spectroscopy. Stereotact Funct Neurosurg 82: 90-97, 2004.
40. Miller BL, Chang L, Booth R, et al: In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 58: 1929-1935, 1996.
41. Chang L, McBride D, Miller BL, et al: Localized in vivo 1Hmagnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimaging 5: 157-163, 1995.
42. Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA and Gonzalez RG: Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy. Neurooncology 2: 87-95, 2000.
43. Daly PF, Lyon RC, Faustino PJ and Cohen JS: Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J Biol Chem 262: 14875-14878, 1987.
44. Daly PF and Cohen JS: Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review. Cancer Res 49: 770-779, 1989.
45. Gillies RJ, Barry JA and Ross BD: In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells. Magn Reson Med 32: 310-318, 1994.
46. Aiken NR and Gillies RJ: Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res 16: 1393-1397, 1996.
47. Mahmood U, Alfieri AA, Thaler H, Cowburn D and Koutcher JA: Radiation dose-dependent changes in tumor metabolism measured by 31P nuclear magnetic resonance spectroscopy. Cancer Res 54: 4885-4891, 1994.
48. Aiken NR, Szwergold ES, Kappler F, et al: Metabolism of phosphonium choline by rat-2 fibroblasts: effects of mitogenic stimulation studied using 31P NMR spectroscopy. Anticancer Res 16: 1357-1363, 1996.
49. Ackerstaff E, Pflug BR, Nelson JB and Bhujwalla ZM: Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61: 3599-3603, 2001.
50. Aboagye EO and Bhujwalla ZM: Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59: 80-84, 1999.
51. Bhakoo KK, Williams SR, Florian CL, Land H and Noble MD: Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 56: 4630-4635, 1996.
52. Veale MF, Roberts NJ, King GF and King NJ: The generation of 1H-NMR-detectable mobile lipid in stimulated lymphocytes: relationship to cellular activation, the cell cycle, and phosphatidylcholine-specific phospholipase C. Biochem Biophys Res Commun 239: 868-874, 1997.
53. Li X, Jin H, Lu Y, Oh J, Chang S and Nelson SJ: Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 17: 10-20, 2004.
54. Warren KE, Frank JA, Black JL, et al: Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 18: 1020-1026, 2000.
55. Oh J, Henry RG, Pirzkall A, et al: Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19: 546-554, 2004.
56. Lakhani SR and Ashworth A: Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer 1: 151-157, 2001.